<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38724258</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>152</Volume><PubDate><Year>2024</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Epidemiology and infection</Title><ISOAbbreviation>Epidemiol Infect</ISOAbbreviation></Journal><ArticleTitle>Long-term outcomes of SARS-CoV-2 variants and other respiratory infections: evidence from the Virus Watch prospective cohort in England.</ArticleTitle><Pagination><StartPage>e77</StartPage><MedlinePgn>e77</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e77</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0950268824000748</ELocationID><Abstract><AbstractText>This study compared the likelihood of long-term sequelae following infection with SARS-CoV-2 variants, other acute respiratory infections (ARIs) and non-infected individuals. Participants (n=5,630) were drawn from Virus Watch, a prospective community cohort investigating SARS-CoV-2 epidemiology in England. Using logistic regression, we compared predicted probabilities of developing long-term symptoms (&gt;2 months) during different variant dominance periods according to infection status (SARS-CoV-2, other ARI, or no infection), adjusting for confounding by demographic and clinical factors and vaccination status. SARS-CoV-2 infection during early variant periods up to Omicron BA.1 was associated with greater probability of long-term sequalae (adjusted predicted probability (PP) range 0.27, 95% CI = 0.22-0.33 to 0.34, 95% CI = 0.25-0.43) compared with later Omicron sub-variants (PP range 0.11, 95% CI 0.08-0.15 to 0.14, 95% CI 0.10-0.18). While differences between SARS-CoV-2 and other ARIs (PP range 0.08, 95% CI 0.04-0.11 to 0.23, 95% CI 0.18-0.28) varied by period, all post-infection estimates substantially exceeded those for non-infected participants (PP range 0.01, 95% CI 0.00, 0.02 to 0.03, 95% CI 0.01-0.06). Variant was an important predictor of SARS-CoV-2 post-infection sequalae, with recent Omicron sub-variants demonstrating similar probabilities to other contemporaneous ARIs. Further aetiological investigation including between-pathogen comparison is recommended.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beale</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4038-7460</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yavlinsky</LastName><ForeName>Alexei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Wing L E</ForeName><Initials>WLE</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Vincent G</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Epidemiology and Health Care, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovar</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>Theo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wulf Hanson</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayward</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Institute of Epidemiology and Health Care, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abubakar</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Population Health Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldridge</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>206602</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC 19070</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V028375/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Epidemiol Infect</MedlineTA><NlmUniqueID>8703737</NlmUniqueID><ISSNLinking>0950-2688</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long Covid</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">post-viral syndromes</Keyword></KeywordList><CoiStatement>A.C.H. serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>10</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>9</Day><Hour>21</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38724258</ArticleId><ArticleId IdType="pmc">PMC11106725</ArticleId><ArticleId IdType="doi">10.1017/S0950268824000748</ArticleId><ArticleId IdType="pii">S0950268824000748</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organisation. Post COVID-19 condition (Long COVID) [Internet]. [cited 2024 Mar 1]. Available at https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM and Topol EJ (2023) Long COVID: Major findings, mechanisms and recommendations. Nature Reviews Microbiology 21(3), 133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L (2022) Post-COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years &#x2013; United States, March 2020&#x2013;November 2021. Morbity and mortality weekly report [Internet]. [cited 2024 Mar 1];71. Available at https://www.cdc.gov/mmwr/volumes/71/wr/mm7121e1.htm.</Citation></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. (2023) The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. eClinicalMedicine 1, 55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ and Boyton RJ (2023) The immunology of long COVID. Nature Reviews Immunology 23(10), 618&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MF, Cotler J and Jason LA (2020) Post-viral fatigue and COVID-19: Lessons from past epidemics. Fatigue: Biomedicine, Health &amp; Behavior 8, 61.</Citation></Reference><Reference><Citation>Iwasaki A and Putrino D (2023) Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infectious Diseases 23(4), 393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9928485</ArticleId><ArticleId IdType="pubmed">36967698</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. (2023) Risk factors associated with post&#x2212;COVID-19 condition: A systematic review and meta-analysis. JAMA Internal Medicine 183(6), 566&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Notarte KI, Peligro PJ, Velasco JV, Ocampo MJ, Henry BM, et al. (2022) Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: A systematic review of the literature. Viruses 14(12), 2629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9785120</ArticleId><ArticleId IdType="pubmed">36560633</ArticleId></ArticleIdList></Reference><Reference><Citation>Du M, Ma Y, Deng J, Liu M and Liu J (2022) Comparison of long COVID-19 caused by different SARS-CoV-2 strains: A systematic review and meta-analysis. International Journal of Environmental Research and Public Health 19(23), 16010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9736973</ArticleId><ArticleId IdType="pubmed">36498103</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S and Steves CJ (2022) Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. The Lancet 399(10343), 2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Atchison CJ, Davies B, Cooper E, Lound A, Whitaker M, Hampshire A, et al. (2023) Long-term physical and mental health impact of COVID-19 on adults in England: Follow-up of a large random community samples [Internet]. medRxiv. [cited 2024 Mar 1]. p. 2023.04.24.23289043. Available at https://www.medrxiv.org/content/10.1101/2023.04.24.23289043v1.abstract.</Citation></Reference><Reference><Citation>Bello-Chavolla OY, Ferm&#xed;n-Mart&#xed;nez CA, Fern&#xe1;ndez-Chirino L, Ram&#xed;rez-Garc&#xed;a D, Vargas-V&#xe1;zquez A, Basile-Alvarez MR, et al. (2023) Nationally representative prevalence and determinants of post-acute sequelae of SARS-CoV-2 infection (Long COVID) amongst Mexican adults in 2022 [Internet]. medRxiv. [cited 2024 Mar 1]. p. 2023.07.10.23292475. Available at https://www.medrxiv.org/content/10.1101/2023.07.10.23292475v1.abstract.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10847769</ArticleId><ArticleId IdType="pubmed">38327277</ArticleId></ArticleIdList></Reference><Reference><Citation>Karyakarte RP, Das R, Rajmane MV, Dudhate S, Agarasen J, Pillai P, et al. (2023) The burden and characteristics of post-COVID-19 conditions among laboratory-confirmed Delta and Omicron COVID-19 cases: A preliminary study from Maharashtra, India. Cureus [Internet]. Sep 8 [cited 2024 Mar 1];15(9). Available at https://www.cureus.com/articles/183536-the-burden-and-characteristics-of-post-covid-19-conditions-among-laboratory-confirmed-delta-and-omicron-covid-19-cases-a-preliminary-study-from-maharashtra-india.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10560400</ArticleId><ArticleId IdType="pubmed">37814744</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Guan Y, Liao Q, Ma Z, Zhang L, Dong J, et al. (2022) Long-term sequelae of different COVID-19 variants: The original strain versus the omicron variant. Global Health &amp; Medicine 4(6), 322&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9773225</ArticleId><ArticleId IdType="pubmed">36589219</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, Sampaio VS, Ozahata MC, Lopes R, Brito AF, Bragatte M, et al. (2023) Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020&#x2013;2022. Infection Control &amp; Hospital Epidemiology 44, 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10755155</ArticleId><ArticleId IdType="pubmed">37272468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandes-Aceituna A, Garcia-Hernandez A and Larumbe-Zabala E (2023) COVID-19 long-term sequelae: Omicron versus alpha and Delta variants. Infectious Diseases 53(5), 104688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9970656</ArticleId><ArticleId IdType="pubmed">36858287</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, Safarpour A, Trujillo KL, Simonson MD, et al. (2022) Prevalence and correlates of long COVID symptoms among US adults. JAMA Network Open. 5(10), e2238804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello R, Mariani F, Mastrantoni L, De Rose C, Zampino G, Munblit D, et al. (2023) Risk factors for post-COVID-19 condition (Long Covid) in children: A prospective cohort study. eClinicalMedicine 1, 59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101848</ArticleId><ArticleId IdType="pubmed">37073325</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Peyser ND, Lin F, Knight SJ, Djibo A, et al. (2023) Factors associated with long COVID symptoms in an online cohort study. Open Forum Infectious Diseases 10(2), ofad047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945931</ArticleId><ArticleId IdType="pubmed">36846611</ArticleId></ArticleIdList></Reference><Reference><Citation>Saigal A, Niklewicz CN, Naidu SB, Bintalib HM, Shah AJ, Seligmann G, et al. (2023) Cross-sectional study evaluating the impact of SARS-CoV-2 variants on long COVID outcomes in UK hospital survivors. BMJ Open Respiratory Research 10(1), e001667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10401240</ArticleId><ArticleId IdType="pubmed">37536948</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation. Statement on the update of WHO&#x2019;s working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest [Internet]. [cited 2024 Mar 1]. Available at https://www.who.int/news/item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10153606</ArticleId><ArticleId IdType="pubmed">37062542</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan H, Wu Y, Goplen NP and Sun J (2022) Immune determinants of chronic sequelae after respiratory viral infection. Science Immunology.</Citation><ArticleIdList><ArticleId IdType="pubmed">35857581</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M and Harrison PJ (2021) Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Medicine 18(9), e1003773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivaldi G, Pfeffer PE, Talaei M, Basera TJ, Shaheen SO and Martineau AR (2023) Long-term symptom profiles after COVID-19 vs other acute respiratory infections: An analysis of data from the COVIDENCE UK study. eClinicalMedicine.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10721552</ArticleId><ArticleId IdType="pubmed">38106559</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward A, Fragaszy E, Kovar J, Nguyen V, Beale S, Byrne T, et al. (2021) Risk factors, symptom reporting, healthcare-seeking behaviour and adherence to public health guidance: Protocol for virus watch, a prospective community cohort study. BMJ Open 11(6), e048042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8230990</ArticleId><ArticleId IdType="pubmed">34162651</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne T, Kovar J, Beale S, Braithwaite I, Fragaszy E, Fong WL, Geismar C, Hoskins S, Navaratnam AM, Nguyen V and Patel P (2023) Cohort Profile: Virus Watch&#x2014;Understanding community incidence, symptom profiles and transmission of COVID-19 in relation to population movement and behaviour. International Journal of Epidemiology 22, dyad087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10555858</ArticleId><ArticleId IdType="pubmed">37349899</ArticleId></ArticleIdList></Reference><Reference><Citation>Geismar C, Fragaszy E, Nguyen V, Fong WLE, Shrotri M, Beale S, et al. (2021) Household serial interval of COVID-19 and the effect of Variant B.1.1.7: Analyses from prospective community cohort study (Virus Watch). Wellcome Open Research, p. 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564743</ArticleId><ArticleId IdType="pubmed">34796276</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. Investigation of SARS-CoV-2 variants: Routine variant data update [Internet]. [cited 2024 Mar 1]. Available at https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-routine-variant-data-update.</Citation></Reference><Reference><Citation>UK Health Security Agency (2021) Investigation of SARS-CoV-2 variants: Technical briefings. [Internet]. [cited 2024 Mar 1]. Available at https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings.</Citation></Reference><Reference><Citation>World Health Organization (2021) A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [Internet]. [cited 2024 Mar 1]. Available at https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Aspinall E. British Foreign Policy Group (2020) [cited 2024 Mar 1]. COVID-19 Timeline. Available at https://bfpg.co.uk/2020/04/covid-19-timeline/.</Citation></Reference><Reference><Citation>UK Health Security Agency. COVID-19: The green book, chapter 14a [Internet]. [cited 2024 Mar 1]. Available at https://www.gov.uk/government/publications/covid-19-the-green-book-chapter-14a.</Citation></Reference><Reference><Citation>National Institute of Health and Care Excellence. Identification and classification [Internet]. [cited 2024 Mar 1]. Available at https://cks.nice.org.uk/topics/obesity/diagnosis/identification-classification/.</Citation></Reference><Reference><Citation>Beale S, Hoskins S, Byrne T, Fong WLE, Fragaszy E, Geismar C, et al. (2023) Differential risk of SARS-CoV-2 infection by occupation: Evidence from the virus watch prospective cohort study in England and Wales. Journal of Occupational Medicine &amp; Toxicology 18(1), 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10068189</ArticleId><ArticleId IdType="pubmed">37013634</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang M, Wu X, Jing H, Novakovic VA and Shi J (2023) The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. Frontiers in Cardiovascular Medicine 10, 1062491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9941162</ArticleId><ArticleId IdType="pubmed">36824451</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobner J and Kaser S (2018) Body mass index and the risk of infection - From underweight to obesity. Clinical Microbiology &amp; Infection 24(1), 24&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">28232162</ArticleId></ArticleIdList></Reference><Reference><Citation>Mize TD (2019) Best practices for estimating, interpreting, and presenting nonlinear interaction effects. Sociological Science 6, 81&#x2013;117.</Citation></Reference><Reference><Citation>Van Buuren S, Groothuis-Oudshoorn K, Vink G, et al. mice: Multivariate Imputation by Chained Equations [Internet]. Available at https://cran.r-project.org/web/packages/mice/index.html.</Citation></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. (2022) Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. Journal of the American Medical Association 328(7), 676&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. Antibody testing for SARS-CoV-2: Extended information for medical professionals and researchers on using and interpreting SARS-CoV-2 antibody tests [Internet]. [cited 2024 Mar 1]. Available at https://www.gov.uk/government/publications/antibody-testing-for-sars-cov-2-extended-information.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>